Agouron Pharmaceuticals (AGPH) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Steve Fancy who wrote (5596)	10/26/1998 1:21:00 PM
From: scaram(o)uche	Read Replies (1) of 6136

Steve: Largely data that we already knew about. The 13/15 versus 6/12 data, the ''<1 copy/ml (OD=background) at 32 weeks" data, is the important part. If they only looked at 32 weeks, I'm relatively impressed.......the data helps to keep my skeptical mind open. If they looked at other time points, I'd like to know about it..... I hate companies that give selected data. Viral vaccines have not done well as therapeutics, but HIV is a whole new creature. I continue to believe that the concept of HAART plus a vaccine is worth testing, and, regardless of opinion regarding outcome, we should all be happy that IMNR is giving it a shot. As before, this is a "show me" project, a project that faces skepticism from FDA and most immunologists. My bottom line??.... if I were HIV positive, I'd want in the phase III. I would not be enthusiastic about the outcome, but I'd want in. Rick

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next